Introduction of a pilot program to measure and improve the clinical care of melanoma patients in the Lower Silesian Voivodeship in Poland: a report of 20 months experience

• Published in: BMC cancer Vol. 22; no. 1; p. 1207
• Main Authors: Ziętek, Marcin, Wierzbicki, Jędrzej, Pawlak, Edyta, Maciejczyk, Adam, Matkowski, Rafał
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 23.11.2022; BioMed Central; BMC
• Subjects: Benchmarking; Benchmarks; Biopsy; Cancer therapies; Care and treatment; Chemotherapy; Diagnosis; Diagnostic tests; Hematology; Humans; Lymph nodes; Medical care; Medical Oncology; Melanoma; Melanoma - diagnosis; Melanoma - epidemiology; Melanoma - therapy; Metastasis; Methods; Patient pathway; Patients; Pilot Projects; Pilot study; Poland - epidemiology; Quality indicators; Quality management; Radiation therapy; Skin cancer; Skin Neoplasms - diagnosis; Skin Neoplasms - epidemiology; Skin Neoplasms - therapy; Surgery; Tomography; Poland; Pilot study; Quality indicators; Benchmarking; Patient pathway; Melanoma
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-10253-8

In recent years, benchmarking and assessment methods to improve the quality of care have become increasingly important. Such approaches allow for a uniform assessment, comparisons between centers or over time, and the identification of weaknesses. In this study, the results of a 20-month pilot program to assess, monitor and improve the quality of care in melanoma patients primarily treated surgically are presented. The pilot program started in May 2020 at the Lower Silesian Oncology, Pulmonology and Hematology Center (LSOPHC) in Wroclaw, Poland (Lower Silesian Voivodeship, southwestern province of Poland with a population of 2,9 million). The program involved the introduction of a synoptic histopathological protocol, medical coordinators, and a set of measures to assess oncological care. In total, 11 Skin Cancer Unit (SCU) measures were introduced to analyze clinical outcomes, diagnostic quality, and duration. Data from 352 patients covered by the program were analyzed. In addition, the completeness of diagnostics from external sites was compared to our own results. Furthermore, the timeliness of the initial diagnostic tests and in-depth diagnostics were assessed and compared to the timeliness before implementation of the pilot program. The introduced measures assessed the mortality related to oncological treatment, the rate of complications, advanced stages of melanoma, the completeness and duration of diagnostics, the involved nodes after lymphadenectomy, and melanoma screening. During the study period, the timeliness of the initial diagnostics was maintained at 87.8%, and the timeliness of the in-depth diagnostics at 89.5%. Compared to a similar period before the program, these values were 36.1% and 67.5%, respectively. The introduced measures seem to be effective and practical tools for benchmarking clinical and diagnostic aspects. They also allowed for a sensitive assessment of individual issues and indicated sensitive points. Furthermore, the actions undertaken in this pilot program allowed for a shortening of the duration of diagnostics.